Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321105 | 0.80 | GPR84 (0.35) | KCNH2GPR84CXCR5SLC2A1KDM4E | |
| SCHEMBL10318892 | 0.78 | KCNH2 (0.34) | KCNH2GPR84CXCR5CYSLTR2CYSLTR1 | |
| SCHEMBL10318533 | 0.76 | KCNH2 (0.33) | KCNH2GPR84CXCR5 | |
| SCHEMBL10318108 | 0.75 | KCNH2 (0.33) | KCNH2GPR84CXCR5 | |
| SCHEMBL10317621 | 0.74 | CYSLTR2 (0.34) | CYSLTR2CYSLTR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL10318659 | 0.74 | ADRA2B (0.30) | — | |
| SCHEMBL10318090 | 0.74 | CXCR5 (0.34) | KCNH2GPR84CXCR5CYSLTR2CYSLTR1 | |
| SCHEMBL10317803 | 0.74 | KCNH2 (0.31) | KCNH2GPR84CXCR5 | |
| SCHEMBL10320396 | 0.72 | HSD11B1 (0.34) | GPR84 | |
| SCHEMBL28296316 | 0.72 | KCNH2 (0.54) | KCNH2GPR84CXCR5CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919300-B2 | 1-hexene production process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2484685-B1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2484685-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | Sumitomo Chemical Co., Ltd (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | AP1M1, HK1, CYC1 | KCNH2 1395/4885GPR84 3260/4885CXCR5 1612/4885 |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | AP1M1, AP3M1, EMC1 | KCNH2 1048/4885GPR84 3787/4885CXCR5 2651/4885 |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | AP1M1, AMY1A, AP3M1 | KCNH2 2478/4885GPR84 2592/4885CXCR5 1695/4885 |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | EMC1, CYC1, AP1M1 | KCNH2 2322/4885GPR84 4568/4885CXCR5 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.